Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cardiovascular syndrome X and endothelial dysfunction].

Eugenia Vázquez-Rey1, Juan Carlos Kaski

  • 1Coronary Artery Disease Research Unit, Department of Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom.

Revista Espanola De Cardiologia
|February 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy.

The pharmacogenomics journal·2026
Same author

Cardiovascular pharmacotherapy in 2025.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.

European heart journal·2026
Same author

Exercise treadmill testing for efficacy evaluation in randomized, controlled trials.

American heart journal·2026
Same author

Optimizing cardiovascular pharmacotherapy in older adults with frailty.

Nature reviews. Cardiology·2026
Same author

Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.

European journal of heart failure·2025

Cardiovascular Syndrome X, characterized by chest pain despite normal coronary angiograms, is often linked to endothelial dysfunction. This review explores the evidence for impaired coronary microcirculation as a key factor in this condition.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Internal Medicine

Context:

  • Up to 30% of patients with chest pain exhibit normal coronary angiograms.
  • Cardiovascular Syndrome X (CSX) is diagnosed in patients with typical angina and positive stress tests but no obstructive coronary artery disease.
  • The syndrome is clinically and pathogenically heterogeneous, necessitating investigation into underlying mechanisms.

Purpose:

  • To review the evidence linking endothelial dysfunction to Cardiovascular Syndrome X.
  • To explore the role of coronary microcirculation impairment in CSX pathophysiology.
  • To consolidate current understanding of CSX mechanisms.

Summary:

  • Endothelial dysfunction, particularly affecting the coronary microcirculation, is a prominent proposed mechanism for CSX.

Related Experiment Videos

  • This review synthesizes research on endothelial dysfunction as a cause of chest pain and ischemic ST depression in CSX patients.
  • Evidence suggests impaired endothelial function contributes significantly to the symptoms observed in CSX.

    • Impact:

    • Highlights endothelial dysfunction as a critical area for CSX research and potential therapeutic targets.
    • Improves understanding of a common yet complex clinical presentation (CSX).
    • Provides a foundation for future studies investigating microvascular function in ischemic heart disease.